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Our aim was first to evaluate the association between blood vessel density (BVD) and free platinum concentration in experimentally
induced tumours in rabbits. We also investigated the association between tumour BVD and the clinical response of patients who had
undergone targeted carboplatin intra-arterial (i.a.) chemoradiotherapy. VX2 carcinoma cells were transplanted into 46 inbred female
Japanese white rabbits. In the i.a. group, carboplatin was infused into the lingual artery, and in the intravenous (i.v.) group, carboplatin
was infused through the auricular vein. In the clinical study, we evaluated 19 patients with squamous cell carcinomas of the oral cavity
and oropharynx, who had undergone targeted carboplatin i.a. chemoradiotherapy and had been administered i.a. tegafur/uracil
chemotherapy before surgery. We quantified angiogenesis in both studies. Increased BVD was associated with a higher free platinum
concentration in the tumour region in the i.a. group of rabbits. In the clinical study, using multivariate logistic regression analysis, only
the BVD was related independently to the treatment effect. Therefore, BVD is a valid predictor of the effects of i.a. targeted
carboplatin chemotherapy and concurrent radiotherapy for treating human oral and oropharyngeal squamous cell carcinomas.
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The anticancer effect of superselective chemotherapy is believed to
be reinforced when highly concentrated drugs are administered to
tumours via supplying arteries (Kar et al, 1986; Moses et al, 1993).
However, little evidence has been reported from experimental
trials in the oral region. We also hypothesise that the concentration
of anticancer drug in a tumour may be associated with the blood
vessel density (BVD) in the tumour. Consequently, BVD may
influence therapeutic effects, in that different treatment effects may
be caused partly by differences in the degree of vascularity of a
tumour. Much experimental evidence has shown that tumour
growth and metastasis depend on local angiogenesis (Folkman and
Klagsbrun, 1987; Horak et al, 1992; Macchiarini et al, 1992) but no
study has elucidated the relationship between the effects of
chemotherapy and tumour angiogenesis. This study was designed
to evaluate the relationship between BVD and free platinum
concentrations during intra-arterial (i.a.) chemotherapy. Using
transplanted VX2 tongue tumour cells in Japanese white rabbits,
and a series of 19 human patients, we evaluated the association
between BVD and the effects of concurrent targeted i.a. carboplatin
chemotherapy and radiotherapy before surgery in squamous cell
carcinomas of the oral cavity and oropharynx.
MATERIALS AND METHODS
Experimental study
Inbred female Japanese white rabbits weighing 3–4kg were used
throughout the experiment. The animals were anaesthetised via the
auricular vein using pentobarbital sodium (1mgkg
 1), and then
VX2 carcinoma cells were implanted as 0.2ml injections of cell
suspension into the tongue, using a 22-gauge needle. By 3 weeks
after implantation, the tumours had grown to 2.0cm
2, which
enabled us to evaluate the free platinum concentration.
For i.a. carboplatin infusion, a 29-gauge catheter was introduced
into the lingual artery on the VX2-transplanted side in 26 rabbits
kept under general anaesthesia. Access to this artery was gained
via the arterial branch of the submandibular gland (Figure 1). The
catheter was connected to tubing and the drug was injected with a
constant infusion pump. Indigo carmine was injected via the
catheter to confirm whether the infused carboplatin would be
appropriately distributed in the tongue (Figure 2). Carboplatin was
then infused at a dose of 6mgkg
 1 of body weight over about 20s.
Heparin (5000Ul
 1) and methylprednisolone (2mganimal
 1)
were added to prevent thromboses and spasms at the catheterisa-
tion site. For intravenous (i.v.) carboplatin delivery, a similar
catheter was positioned in the auricular vein on the VX2-
transplanted side and the same dose of carboplatin was then
infused. To measure the concentrations of blood vessels, we
excised tongue tissue specimens in the tumour and normal regions
immediately after the injection of carboplatin. The blood vessels
were stained with factor-VIII-related antigen using a standard
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simmunoperoxidase technique (Figure 3). The most vascular areas
of the tumour were viewed at low magnification, and the vessels
were counted in four fields at  200 (corresponding to an area of
0.16mm
2). The highest vascularity count of four fields was used as
the final score.
To measure free platinum concentrations in tissues, we excised
tongue tissue specimens immediately after and at 24h after the
injection of carboplatin. All rabbits were then euthanised and the
kidneys and livers were removed. The free platinum concentration
was measured using an atomic absorption spectrometer (Sumitomo
Material Bioscience Corp, Tokyo, Japan).
This experimental study conformed to the ethical guidelines for
animal experimentation of the University of Occupational and
Environmental Health, Kitakyushu, Japan.
Clinical study
Nineteen patients with squamous cell carcinomas of the oral cavity
and oropharynx, who had undergone targeted i.a. carboplatin
infusions with concurrent radiotherapy and the oral administra-
tion of tegafur/uracil (UFT
s) before surgery at the University
Hospital of Occupational and Environmental Health, Japan, were
examined between April 1995 and February 2002 (Table 1). All
patients included in this study had to have previously untreated,
histologically proven squamous cell carcinomas of type T3, T4 or
T2 (a strong tendency to infiltration and a diameter of greater than
3cm), arising from the oral cavity and oropharynx, with any N
status, but without distant metastases. Patients with a performance
status of 0–1 according to the World Health Organization scale
were eligible. All patients also had to have a serum creatinine
concentration of 2.0mgdl
 1 or less, a white-cell count of at least
4000ml
 1, a platelet count of at least 100000ml
 1, and a
haemoglobin (Hb) concentration of at least 10.0gdl
 1. In addition,
the AST and ALT values needed to be less than 50IUl
 1 with
bilirubin values less than 2.0mgdl
 1. All patients provided
informed consent for participation in this treatment. The median
age of the patients was 67 years (range, 43–78; mean 63.1); six
were women and 13 were men. These patients were staged
according to the UICC–TNM staging system (Hermanek and
Sobin, 1987), based on the pattern of invasion described by
Anneroth et al (1987). This consisted of four categories: Grade 1,
tumours showed invasive, well-delineated borders; Grade 2,
infiltrating, solid cords, bands and strands; Grade 3, small groups
or cords of infiltrating cells (n415); Grade 4, marked and
widespread cellular dissociation in a small group of cells (no15)
and/or in single cells. We recorded the lowest Hb levels observed
during chemoradiation. Haemoglobin concentrations were classed
as low (p11.5gdl
 1) or high (411.5gdl
 1). All patients were
followed up for at least 2 years.
All patients in the series were administered oral tegafur/uracil
(400–600mgday
 1), from the time histological diagnosis was
determined until the completion of their courses of radiation
therapy and chemotherapy. For the carboplatin infusions, a
microcatheter was introduced angiographically by a radiologist
to the artery supplying the tumour. Because occasionally the
tumour stain could not be observed with digital subtraction, an
injection of indigo carmine via the catheter was used to determine
whether the infused carboplatin was dispersed appropriately
through the tumour. The carboplatin was then infused at a dose
Lingual artery
29 G catheter
Carotid artery
Submandibular grand
Figure 1 Intra-arterial infusion was accomplished by incising the midline
of the neck. After the left carotid and facial arteries were isolated, a 29-
Gauge catheter was introduced into the tongue artery by way of the
submandibular branch.
Figure 2 The injection of indigocarmine via the catheter indicated
whether the infused carboplatin appropriately access the tongue at the
cancerous site.
Figure 3 Microvessel staining. Blood microvessels were stained with
CD31 using a standard immunoperoxiderse-staining technique. All sections
were routinely processed, cut into 4mm thick sections and then were
stained using the LSAB (labelled streptavidin–biotin) method.
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sbased either on the patient’s body surface area (350mgm
 2), or
according to Calvert’s formula (4.5 times the area under the curve,
AUC) after renal function had been assessed (Calvert et al, 1989;
Oya et al, 2004). It was administered within about 20s. When
multiple nutrient arteries were present, the dose of carboplatin for
each artery was determined based on the percentage of tumour
stained with indigo carmine after each vascular infusion. Heparin
sodium (2000Uh
 1) and methylprednisolone (125mg) were added
to the infusions to prevent thromboses and spasms at the
catheterisation site. This targeted i.a. chemotherapy was performed
after about 10Gy irradiation. Irradiation was administered by an
external beam X-ray targeted to the primary sites. This consisted of
doses of 1.5Gy per fraction, twice daily with a minimum of 6h
between fractions, administered 5 days a week with a total dosage
of 30Gy over 2 weeks.
Tumour angiogenesis
Tumour specimens in which BVD was to be measured were
obtained from diagnostic biopsy specimens before any treatments
were begun. Blood microvessels were stained for CD31 protein
using a standard immunoperoxidase technique. All sections were
processed routinely; sections (4mm) were cut and counterstained
using streptavidin–biotin labelling. Counting was made by a
researcher with no knowledge of the treatment for individual
patients. Counts were made of the numbers of vessels per  200
microscope objective field. Angiogenesis was evaluated using an
established method (Vermeulen et al, 1996). The means and
standard deviations of all counts were calculated. Blood vessel
density counts were divided into two groups based on the median
BVD measured from 117 patients with squamous cell carcinomas
of the oral cavity and oropharynx who were treated at our
university hospital between June 1986 and February 2002. The
counts were recorded as high (X11 per field) or low (o11 per
field).
Estimation of response to treatment
To estimate the response to targeted i.a. carboplatin infusion and
concurrent radiotherapy, we evaluated formalin-fixed paraffin-
embedded sections (4mm) of tumour tissues taken from all
patients at resectional surgery. Sections with no viable tumour cells
in the tissue were graded histologically as a complete response
(CR); those with at least some viable tumour cells were graded as
an incomplete response (ICR).
Statistics
We used the Mann–Whitney U-test and Spearman’s correlation
coefficient for nonparametric analysis. We used a logistic
regression model to analyse multivariate relationships between
BVD and treatment response and other prognostic factors. The
survival rates were calculated by the Kaplan–Meier method and
compared using log-rank tests. All calculations were performed
using the Stat View version 5J software package (Abacus Concepts,
Inc., Berkley, CA, USA). Statistical significance was defined as
Po0.05.
RESULTS
Experimental study
The median BVD in the tumour region of rabbits was
13countsfield
 1 with a range of 8–21, whereas BVD in the
normal region was 7.0countsfield
 1, with a range of 3–11
(Po0.001). The concentrations of platinum in tongue tissue
specimens are shown in Figure 4. Levels of the i.a. group were
significantly higher than in the i.v. group. The higher BVD was
associated with a higher free platinum concentration in the tumour
region in the i.a. group (Spearman’s r¼0.797, P¼0.0003;
Figure 5). Platinum concentrations were compared between the
VX2 tumours and normal tissue specimens. In both groups, tissue
platinum concentrations were higher in the tumours than in the
normal regions, and the differences were statistically significant
(i.a. group, Po0.0001; i.v. group, P¼0.0059).
To evaluate the carboplatin distribution in other organs
according to the infusion routes, we measured platinum concen-
trations in the kidneys and liver. We found no differences in the
platinum concentrations of both organs between the i.a. and i.v.
groups (Figure 6).
Clinical study
Distribution of vascularisation counts in biopsy specimens For the
19 patients reviewed in this study, the median microvessel count
for CD31 was 13 counts per  200 microscope objective field
(range, 6–18countsfield
 1). Twelve patients were classified as a
CR and seven as an ICR. The median BVD within the carcinomas
Table 1 Characteristics of the 19 patients studied
Age range (years) 43–78
Mean age (years) 63.1
Sex (number of patients)
Male 13
Female 6
Site of primary tumour (number of patients)
Tongue 6
Gingiva 7
Buccal mucosa 4
Oral floor 1
Soft palate 1
T stage (number of patients)
T2 8
T3 2
T4 9
Haemoglobin level
Median. 11.5gdl
 1; range: 8.6–15.7
Low(p11.5gdl
 1)1 0
High(411.5gdl
 1)9
Differentiation (number of patients)
Poor 10
Moderate 2
Well 7
Pattern of invasion (number of patients)
II 3
III 6
IV 10
Expression of EGFR (number of patients)
Negative 12
Positive 7
Expression of VEGF (number of patients)
Negative 8
Positive 11
MVD
Median;13countsunit
 1, range; 6–18
Low (MVDp11countsunit
 1)7
High (MVD411countsunit
 1)1 2
BVD¼blood vessel density; EGFR¼epidermal growth factor receptor; VEGF¼
vascular endothelial growth factor.
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sof the CR patients was 14countsfield
 1 (range, 8–18). In contrast,
the median BVD in the tumours from ICR patients was
11countsfield
 1 (range, 6–18 counts/field). The patients were
divided into two groups based on BVDs: low-density
(p11countsfield
 1) and high-density (411countsfield
 1), and
the relationship between BVD and the histological response to
treatment was examined. In the high-density group, 10 of 12
patients were classed as CR, whereas in the low-density group, two
of seven patients were CR (Table 2).
Relationship between response to treatment and other prognostic
parameters In the group with tissues staining positive for
expressed epidermal growth factor receptor (EGFR), two of seven
patients were classed as CR, whereas in the negative EGFR
expression group, 10 of 12 patients were CR (P¼0.0267). No
meaningful correlation could be identified with factors such as age,
T classification, degree of histological specialisation, pattern of
invasion, vascular endothelial growth factor (VEGF) expression,
the lowest Hb level during chemoradiation, or histological
treatment effects (Table 2).
In a multivariate logistic regression analysis, only BVD was
independently related to the treatment effect (P¼0.0105; odds
ratio, 30.00; 95% CI, 2.216–406.083) (Table 3).
The 5-year disease-specific survival rate for the patients in the
low BVD group was 14%, whereas that for the high BVD group was
83% (P¼0.014; Figure 7). The 5-year overall survival rate for the
patients in the low BVD group was also 14%, but for the high BVD
group it was 75% (P¼0.0121; Figure 8).
DISCUSSION
In this experimental study, we used a rabbit tongue model of
cancer to evaluate targeted i.a. infusion chemotherapy. Many
experimental studies using this approach have been reported, but
none has used oral tissues and fine-catheter insertion (Figures 1
and 2). We introduced a fine 29-gauge catheter into the lingual
artery via the arterial branch of the submandibular gland. This
method provided a clear visual field and reliable catheter fixation,
allowing us to obtain stable data regarding platinum concentra-
tions in the tongue.
Targeted i.a. injection chemotherapy is considered effective
because the anticancer drug is selectively administered via the
feeding artery of the tumour and results in a high concentration of
drug in the affected tissue. However, many factors affect the
distribution of anticancer drugs to tumours. In this study, we paid
special attention to the BVD of the tumour as one factor that can
influence anticancer drug distribution. Many reports have
indicated that BVD is related to both metastasis and survival rate,
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Figure 4 Tissue platinum concentrations of the VX2 tongue tumour
region from 46 rabbits after the administration of carboplatin. In
comparison with i.v. infusion (n¼26, median¼7.98mgg
 1), the i.a.
infusion method showed a higher carboplatin concentration in the tongue
tissue (n¼20, median¼80.45mgg
 1) immediately after the administration
of carboplatin. But 24h after the administration of carboplatin, no
difference in the tissue platinum concentration of i.a. and i.v.infusion was
observed.
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Figure 5 Spearman’s correlation coefficients were used to evaluate the
increase in the BVD correlated with the free platinum concentration of the
tongue tissue. In the i.a. infusion group, the increase in the BVD was
associated with a higher free platinum concentration in the tumour region.
(Spearman r¼0.797). However, no relationship was observed between
the platinum concentration in the i.v. infusion group and in the normal
region of the i.a. infusion group with the BVD.
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Figure 6 Concentration of platinum in the kidney and the liver at 24h
after the administration of carboplatin. At 24h, median platinum
concentration in the kidney of the i.v. infusion group was 2.19mgg
 1,
whereas in the i.a. infusion group it was 3.22mgg
 1. In the liver, the i.v.
infusion group was 0.92mgg
 1, whereas the i.a. infusion group was
0.74mgg
 1. No statistically significant differences were found regarding the
platinum concentrations in the kidney and the liver of the two groups.
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sand BVD has even been considered an index of malignancy in
some cancers. However, few reports have addressed the effects of
chemotherapy on BVD. Tukuda (1999) reported a relationship
between BVD in tumours and the therapeutic effects of
neoadjuvant chemotherapy in head and neck cancers. They
concluded that the higher the BVD, the easier it is for anticancer
drugs to be distributed to the tumour’s focus. Koukourakis et al
(2000) reported that vascularisation was closely related to the
success of chemoradiotherapy, so they designed treatment plans
based on the degree of angiogenesis in the tumour. Although the
relationship between the distribution of anticancer drugs by i.a.
injection and the blood flow of the focus has yet to be clarified,
augmentation of the antitumour effects of drugs by increasing
local blood flow has already been used clinically.
Among the several factors identified to date, Hb level, EGFR
(Neal et al, 1990) and VEGF are all regarded as candidate
influences on the effects of chemoradiation in the treatment of
head and neck cancers. In the present study, EGFR immunostain-
ing in the tumour was found to be a useful factor for making
decisions to use targeted chemoradiotherapy. Sainsbury et al
(1987) reported that, for patients with breast cancer, being EGFR-
positive is significantly associated with a poor prognosis. We used
immunohistochemistry to visualise EGFR in the tissue. However,
this method was difficult to evaluate objectively, and we could not
identify a significant relationship between EGFR level and the
treatment effect using multivariate analysis.
Strong evidence from retrospective studies suggests that
anaemia not only reflects a biologically more aggressive tumour,
but that it may be a mediating factor in resistance to radiotherapy
(Bush, 1986; Dische, 1991; Obermair et al, 2001). In our study, no
relationship was observed between Hb levels and the targeted
chemoradiation effect. This may have reflected differences between
whole body Hb level and that in the tumour, or heterogeneity in
oxyhaemoglobin (HbO2) saturation within the tissue. Vaupel et al
(1989) measured HbO2 data for erythrocytes from various
distributions, and found substantial variations in oxygenation
status between four different cryobiopsies of the same metastatic
Table 2 Univariate analysis of clinicopathological factors and response to
treatment
Factor ICR (%) CR (%)
Odds
ratio 95% CI P
Age (years)
p65 4 (41.7) 5 (58.3)
465 3 (30.0) 7 (70.0) 1.867 0.283–12.312 0.5166
T stage
T1+T2 2(25) 6 (75)
T3+T4 5 (45.5) 6 (54.5) 0.40 0.055–2.934 0.3674
Haemoglobin level
Low (p11.5gdl
 1) 4 (40.0) 6 (60.0)
High (411.5gdl
 1) 3 (33.3) 6 (66.7) 1.333 0.311–12.842 0.465
Differentiation
Well 3 (42.9) 4 (57.1)
Moderate+poor 4 (36.4) 8 (63.6) 1.500 0.220–10.220 0.6787
Pattern of invasion
1+2+3 3 (33.3) 6 (66.7)
4 4 (40.0) 6 (60.0) 0.750 0.115–4.899 0.750
Expression of EGFR
Negative 2 (16.7) 10(83.3)
Positive 5 (71.4) 2 (28.6) 0.08 0.009–0.748 0.0267
Expression of VEGF
Negative 3 (37.5) 5 (62.5)
Positive 4 (36.4) 7 (63.6) 0.952 0.144–6.282 0.9596
BVD
Low(p11) 5 (71.4) 2 (28.6)
High(411) 2 (16.7) 10 (83.3) 12.50 1.338–116.82 0.0267
BVD¼blood vessel density; CI¼confidence interval; CR¼complete response;
EGFR¼epidermal growth factor receptor; ICR¼incomplete response; VEGF¼vas-
cular endothelial growth factor.
Table 3 Multivariate analysis of clinicopathological factors and response
to treatment
Factor Odds ratio 95% CI P
T stage
T1+T2 vs T3+T4 0.300 0.030–0.972 0.3036
Haemoglobin level
Low vs high 1.849 0.180–8.948 0.6047
Expression of EGFR
Negative vs positive 0.368 0.039–0.474 0.3826
BVD (CD 31)
p11 vs 411 30.00 2.216–406.083 0.0105
BVD¼blood vessel density; CI¼confidence interval; EGFR¼epidermal growth
factor receptor; VEGF¼vascular endothelial growth factor.
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Figure 7 Five-year disease-specific survival curves stratified by BVD
status.
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Figure 8 Five-year overall survival curves stratified by BVD.
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slesion (Vaupel and Kallinowski, 1987). Such heterogeneities might
have caused differences in the degree of chemoradiation effect on
the tumour cells in the present study.
In this study, we classed two of 12 patients in the high BVD
group as having an ICR, and two of the seven patients in the low
BVD group showed a CR. Our evidence does not explain this
directly, and larger series of patients with oral carcinomas would
probably be required to do so. Various factors, which we did not
examine in this study, may have affected this result. Some excellent
studies on targeted i.a. chemoradiotherapy (Denys et al, 1997;
Doweck et al, 2002; Robbins et al, 2004) have reported that
primary tumour volume, pathologically positive lymph nodes,
tumour regression rate during chemoradiation therapy and total
dose of radiation were important factors for predicting treatment
outcome among patients with advanced head and neck cancers. In
particular, as for lymph node metastases, significant associations
with an increase of BVD were reported for various tumours. In the
present study, four of the 19 patients died of lymph node
metastases, so we intend further studies on this outcome and BVD
in the effects of targeted i.a. chemoradiotherapy. One reason was
that in this clinical study, we used biopsy specimens selected from
the ‘hot spot’ of angiogenesis in each tumour, and this may have
biased the estimation of BVD. The other may have been in the
relation between the function and size of blood vessels. Hannen
and Riediger (2004) reported that large blood vessels in tumours
are functional, whereas small ones may represent single endothe-
lial cells without significant perfusion capability. Therefore, there
may be regions of tumours with low blood flows and low local O2
concentrations despite having high BVD.
CONCLUSION
Much experimental evidence has shown that tumour growth and
metastasis are dependent upon tumour angiogenesis. However, few
reports have elucidated the relationship between the effects of
chemotherapy and such angiogenesis. Accurately predicting the
effects of neoadjuvant chemoradiotherapy for patients with
advanced oral cancer is important for the selection of optimal
treatment strategies and regimens.
We have identified a close correlation between BVD and the
concentration of anticancer drugs in tissues. These data suggest
that the BVD of a tumour predicts the effects of targeted
carboplatin i.a. chemotherapy for oral cancer.
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